Preferences help
enabled [disable] Abstract
Number of results
2018 | 20 | 215-225
Article title

Improvement in CD4 cells counts in newly diagnosed HIV infected Cameroonian patients under HARRT is counterbalanced by the mild deleterious effects of antiretroviral therapy on liver function: a longitudinal study

Title variants
Languages of publication
Human immunodeficiency virus (HIV) infection still is a worldwide public health concern, but especially so in Cameroon. Still, the health of HIV-infected people has greatly improved following the introduction of highly active antiretroviral therapy (HAART). Conversely, some authors reported the occurrence of side effects. Unfortunately, data on the topic are scarce in Cameroon. This study aimed at investigating the impact of HAART on liver function in newly diagnosed HIV-infected people. An 18-month longitudinal study was carried out in a health facility in the town of Douala, Cameroon. Investigative methods relied on a questionnaire approach, clinical and biological analyses and medical records exploitation. A total of 107 patients aged 18-45 years old were included in the study. Most participants were females (94, 87.9%) and aged 30-40 years (60, 56.1%). A higher significant fraction of patients had CD4 lymphocytes counts less than 200 cells/mm3 (42, 39.3%) at baseline. We recorded a 1.5-fold increment in the CD4 lymphocytes counts over the follow up period (P-value < 0.0001). Indeed, globally, a significant increasing in ALT level was recorded over follow up. There is a critical need for paying attention to liver function in people living with HIV/AIDS and under therapy.
Physical description
  • Department of Animal Organisms, The University of Douala, Douala, Cameroon
  • Institute for Applied Sciences, Douala, Cameroon
  • Department of Biochemistry, The University of Douala, Douala, Cameroon
  • Department of Medical Laboratory Science, University of Buea, Buea, Cameroon
  • District Hospital of Deido, Douala, Cameroon
  • [1] ONUSIDA. (2018). Statistiques mondiales sur le VIH en 2017. Available at:
  • [2] Kalyesubula R., Perazella M. (2009). HIV-related nephrotoxicity in Sub-Saharan Africa. The Internet J Virol 6 (1): 1-10.
  • [3] Kontorinis N., Dieterich D. (2003). Hepatoxicity of antiretroviral therapy. AIDS Rev 5: 36-43.
  • [4] Lucien K.F.H., Clement A.N.J., Fon N.P., Weledji P., Ndikvu C0P. (2010). The effects of antiretroviral treatment on liver function enzymes among HIV-infected out patients attending the central. Afr J Clin Exper Microbiol 11(3): 174-178.
  • [5] Kamga H.L.F., Assob J.C.N., Njunda A.L., Nde Fon P., Nsagha D.S., Atanga M.B.S., Weledji P., Puinta D.P., Achidi E.A. (2011). The kidney function trends in human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) patients at the Nylon District Hospital, Douala, Cameroon. J AIDS and HIV Res 3(2): 30-37.
  • [6] Nuñez M.J., Martin-Carbonero L., Moreno V., Valencia E., Garcia-Samaniego J., Gonzalez-Castillo J. (2006) Impact of antiretroviral. AIDS 22: 825-829.
  • [7] EDS-MICS. (2012). Rapport Préliminaire sur la prévalence du VIH. Enquête Démographique et de Santé et à Indicateurs Multiples 2011, 13p. [French]
  • [8] Guidelines for CyFlow counter. Accessed 15 January 2015. Available:
  • [9] Kamgain Mawabo L., Assam Assam J-P., Kojom L.P., Kamga Fouamno H.L. (2016) Impact of malaria infection on renal and liver functions in patients living with HIV/AIDS on HAART in Douala, Cameroon. Scholars J Appl Med Sci 4 (11A): 3916-3920.
  • [10] Mbanya D., Sama M., Tchounwou P. (2008) Current Status of HIV/AIDS in Cameroon: How effective are control Strategies? Inter J Environ Res Pub Health 5 (5): 378-383.
  • [11] Buelli F., Foca E., Odolini S., Pietra V. (2010) Genderuality, pregnancy and procreation desire among HIV+ patients in Ouagadougou, Burkina Faso. J Infect Dis 38 (Suppl I) 66: B20411.
  • [12] Mbopi-kéou F., Dempouo Djomassi L., Monebenimp F. (2012) Aspects descriptifs du VIH / SIDA chez les sujets âgés de 50 ans et plus suivis au Centre de Traitement Agréé de Bafoussam – Cameroun. Pan Afr Med J, 5: 1-10.
  • [13] Nkoghe D., Nnegue L.P.S., Moutschen M., Demonty J. (2002) Prise en charge des patients infectés par le VIH : Expérience du CHU de Liège RMLG. Rev Med Liège 57 (8): 546 -551.
  • [14] Nadembaego W., Giannella S., Simpore J., Ceccherini S., Pietra V., Colizzi V., Perno C., Musumeei S. (2006) Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol 78: 1385-1391.
  • [15] Dimodi H., Sone Etame L., Signing Nguimkeng B., Essouman Mbappe F., Essola Ndoe N., Nkougni Tchinda J., Abega Ebene J., Ntentié F., Azantsa Kingue G., Mbong A.M., Djiokeng Paka G., Kouanfack C., Ngondi J., Oben Eyong J. (2014) Prevalence of Metabolic Syndrome in HIV-Infected Cameroonian Patients. World J AIDS 4: 85-92.
  • [16] Essomba E., Tsagadigui J., Bita Fouda A., Abessougoue I., Minkemdeffo D., Tsakam S., Etang A. (2013) Point sur la situation des antirétroviraux au Cameroun en 2013. Rev Med Pharm 3(1): 300-306.
  • [17] Addisu A., Dagim A., Tadele E., Adissu A., Mussie A., Filmon K. (2015) CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigrey, Northern Ethiopia: A retrospective cross sectional study. PLoS One 10 (3): e0122583.
  • [18] Sharma A., Wanchu A., Bansal V., Singh S., Varma S. (2007) Improvement in CD4 counts in HIV positive patients treated with HAART and antitubercular drugs: an observational study from North India. Indian J Pathol Microbiol 50 (4): 905-907.
  • [19] Smith CJ, Cropley I, Sabin CA, Johnson MA, Youle MS, Kinloch-de Loes S, Phillips AN. (2004). Factors Influencing Increases in CD4 Cell Counts of HIV-Positive Persons Receiving Long-Term Highly Active Antiretroviral Therapy. The Journal of Infectious diseases 190: 1860-1868.
  • [20] Peters D.E., Uwakwe A.A., Monago C.C. (2014) Effect of antiretroviral drug (arved) on hepatic enzymes in albino rats. J Appl Sci Environ Manage 18(2): 351-357.
  • [21] Aashish P., Tarun S., Pallavi B. (2012) Drug-Induced Hepatotoxicity: A Review. J Appl Pharm Sci 5: 233-243.
  • [22] Giannini E.G., Testa R., Savarino V. (2005) Liver enzyme alteration: a guide for clinicians. Can Med Ass J 172 (3): 367- 379.
  • [23] Xiao J., Du S., Gao G., Yang D., Zhao H. (2016) Drug-Induced Liver Injury in HIV-Infected Patients with Opportunistic Infections: Causes, Clinical Features and Predictors in Chinese Patients. J AIDS Clin Res 7: 7.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.